Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-tim🥃e costs caused the company to miss p🏅rofit estimates despite better-than-expected sales.

Sales of the company's pharmaceuticals and medical devices rose just over 4% from the same time last year to $22.45 billion, better than the $22.38 billion analysts had expected, according to consensus estimates compiled by Visible Alpha. However, profits fell short of estimates due to various one-time costs like legal fees and 澳洲幸运5开奖号码历史查询:asset amortization costs.

Johnson & Johnson reported $4.69 billion in net income, short of the $5.66 billౠion analysts had expected. After accounting for the one-t﷽ime expenses, however, the company posted $6.84 billion in adjusted net income, or $2.82 per share, better than the $6.59 billion and $2.71 per share analysts had anticipated.

JNJ Lifts Full-Year Sales Guidance But Lowers Profit Projecti♒ons

The company also shifted its full-year guidance from the last time it 澳洲幸运5开奖号码历史查询:updated the projections to account for the financial 澳洲幸运5开奖号码历史查询:impact of recent acquisitions, raising 🌱its expectations for sales while also projecting lower profits than it had previously.꧅

For the full fiscal year, Johnson & Johnson projects operational sales from $89.2 billion to $89.6 billion, above the previous range of $88.7 billion to $89.1 billion guided in April. However, the company also lowered projections for adjusted 澳洲幸运5开奖号码历史查询:earnings per share (EPS) to a range of 𒉰$9.97 to $10.07 from $10.57 to $10.72.

Analysts currently project sales of $88.58 billion and adjusted EPS of $10.42 for the ܫfull year, according to estimates c🌼ompiled by Visible Alpha.

Shares rose 2% as markets opened Wednesday to $154.24 b🐬ut are slightly negative🌄 for 2024.